Legend Biotech has appointed a group of scientific advisors who will provide strategic input as Legend advances its pipeline and future research priorities.
The advisors include Renier Brentjens, Spencer Fisk, Carl June, Maximilian F. Konig, Anthony Polverino and Georg Schett, each bringing deep expertise spanning oncology, immunology, development and manufacturing of cell-based therapies.
Ying Huang, CEO of Legend Biotech, said: “These advisors bring an exceptional breadth of experience that will help guide our scientific priorities and identify new opportunities for innovation.
“As we look to advance and expand beyond our current portfolio, their perspectives will help shape our long-term scientific direction as we build a diversified, next-generation cell therapy pipeline focused on areas of high unmet need.”
Through ongoing engagement, these advisors will contribute their perspectives across emerging science, translational research, clinical development and manufacturing priorities, including the identification of future areas of unmet need.
Collectively, these advisors reinforce the evolution of Legend Biotech as an end-to-end cell therapy company and the advancement of a next-generation pipeline with the potential to expand patient access and unlock new therapeutic possibilities.
Centred in the US, Legend Biotech is focused on CAR-T cell therapy, developing a one-time treatment for relapsed or refractory multiple myeloma in collaboration with Johnson & Johnson.